Xeris Biopharma Holdings, Inc. XERS Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s change in accrued liabilities?
- Xeris Biopharma Holdings, Inc. (XERS) reported change in accrued liabilities of -$1.5M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s change in accrued liabilities changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s change in accrued liabilities increased by 82.6% year-over-year, from -$8.58M to -$1.5M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.